8.33
Bioventus Inc Aktie (BVS) Neueste Nachrichten
(BVS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Ensign Group Invests in Growth With New Facility Acquisitions - TradingView
Canaccord maintains Bioventus stock with $15 target, bullish outlook By Investing.com - Investing.com Australia
Canaccord maintains Bioventus stock with $15 target, bullish outlook - Investing.com India
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Bone Growth Stimulator Market Is Booming Worldwide | Orthofix Medical Inc., Medtronic, Zimmer Biomet, Bioventus Inc - openPR.com
Charles Schwab Investment Management Inc. Grows Position in Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus CFO Mark Leonard sells $53,639 in stock By Investing.com - Investing.com Australia
Bioventus CFO Mark Leonard sells $53,639 in stock - Investing.com India
(BVS) Proactive Strategies - news.stocktradersdaily.com
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates - MSN
Bioventus SVP Katrina Church sells shares worth $9,925 By Investing.com - Investing.com Australia
Bioventus SVP Anthony D’Adamio sells $25,496 in stock - Investing.com India
Bioventus SVP Katrina Church sells shares worth $9,925 - Investing.com India
Europe Viscosupplementation Market Projected To Witness Substantial Growth, 2025-2032: Sanofi S.A., Bioventus - EIN News
Bioventus (NYSE:BVS) Receives “Buy” Rating from Canaccord Genuity Group - Defense World
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
How To Trade (BVS) - news.stocktradersdaily.com
Earnings call transcript: Bioventus Q4 2024 beats revenue forecast, stock surges - Investing.com Australia
Bioventus Earnings Call: Strong Growth & 2025 Outlook - TipRanks
Bioventus Inc. (NASDAQ:BVS) Q4 2024 Earnings Call Transcript - Insider Monkey
Bioventus: Strong Financial Performance and Strategic Growth Drive Buy Rating - TipRanks
Bioventus Full Year 2024 Earnings: Beats Expectations - Yahoo
Bioventus Faces Potential Stock Dilution Risk Amid Resale of 35 Million Shares - TipRanks
Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ... - Yahoo Finance
Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Bioventus Reports Strong 2024 Financial Performance - TipRanks
Bioventus: Q4 Earnings Snapshot - mySA
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results - OrthoSpineNews
Bioventus: A Medical Technology Company on the Move - RagingBull
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million - Benzinga India
Bioventus Shares Rise After Improved 4Q - MarketWatch
Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday - Benzinga
Bioventus Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Bioventus Inc. Reports Earnings Results for the Fourth Quarter Ended December 28, 2024 - Marketscreener.com
Bioventus sees FY25 revenue $560M-$570M, consensus $554.78M - TipRanks
Bioventus Q4 Adjusted Earnings, Revenue Rise; 2025 Outlook Set - Marketscreener.com
Bioventus stock soars 28% on upbeat FY25 guidance following Q4 revenue beat - Investing.com Australia
Bioventus stock soars 28% on upbeat FY25 guidance following Q4 revenue beat By Investing.com - Investing.com South Africa
Bioventus: Q4 Earnings Snapshot -March 11, 2025 at 07:53 am EDT - Marketscreener.com
BIOVENTUS Earnings Results: $BVS Reports Quarterly Earnings - Nasdaq
Bioventus Inc. SEC 10-K Report - TradingView
Bioventus Inc. Reports Strong Q4 and Full-Year 2024 Financial Results - TradingView
Bioventus Delivers Double-Digit Growth, Cuts Debt by $48M in Financial Turnaround - StockTitan
BIOVENTUS Earnings Preview: Recent $BVS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Bioventus Inc. (NYSE:BVS) Shares Purchased by Principal Financial Group Inc. - Defense World
Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues - Simply Wall St
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):